MA28111A1 - Derives des - Google Patents
Derives desInfo
- Publication number
- MA28111A1 MA28111A1 MA28965A MA28965A MA28111A1 MA 28111 A1 MA28111 A1 MA 28111A1 MA 28965 A MA28965 A MA 28965A MA 28965 A MA28965 A MA 28965A MA 28111 A1 MA28111 A1 MA 28111A1
- Authority
- MA
- Morocco
- Prior art keywords
- mch
- anxiety
- obesity
- diabetes
- depression
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Abstract
Dérivés de 3-(4-aminophényl)-thiénopyrimid-4-one servant d'antagonistes de MCH R1 pour le traitement de l'obésité, du diabète, de la dépression et de l'anxiété La présente invention concerne des arylamines nouvelles qui sont des antagonistes du récepteur 1 de l'hormone concentrant la mélanine (MCH R1), des compositions pharmaceutiques les contenant, des procédés pour leur préparation, et leur utilisation dans des médicaments pour le traitement de l'obésité, du diabète, de la dépression et/ou de l'anxiété. Les composés de la présente invention répondent à la formule:
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US51380003P | 2003-10-23 | 2003-10-23 |
Publications (1)
Publication Number | Publication Date |
---|---|
MA28111A1 true MA28111A1 (fr) | 2006-08-01 |
Family
ID=34549304
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA28965A MA28111A1 (fr) | 2003-10-23 | 2006-04-25 | Derives des |
Country Status (15)
Country | Link |
---|---|
US (1) | US20070078125A1 (fr) |
EP (1) | EP1678184A1 (fr) |
JP (1) | JP2007509158A (fr) |
KR (1) | KR20060100412A (fr) |
CN (1) | CN1871242A (fr) |
AU (1) | AU2004285913A1 (fr) |
BR (1) | BRPI0415667A (fr) |
CA (1) | CA2543122A1 (fr) |
CO (1) | CO5690599A2 (fr) |
IL (1) | IL174693A0 (fr) |
MA (1) | MA28111A1 (fr) |
MX (1) | MXPA06003997A (fr) |
NO (1) | NO20061909L (fr) |
WO (1) | WO2005042541A1 (fr) |
ZA (1) | ZA200603181B (fr) |
Families Citing this family (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1907398A1 (fr) * | 2005-07-15 | 2008-04-09 | AstraZeneca AB | Agents thérapeutiques |
ES2322965T3 (es) | 2005-09-30 | 2009-07-02 | F. Hoffmann-La Roche Ag | Derivados de indano como antagonistas de receptores de mch. |
AR056155A1 (es) * | 2005-10-26 | 2007-09-19 | Bristol Myers Squibb Co | Antagonistas del receptor 1 de la hormona de concentracion de melanina no basica |
US7745447B2 (en) | 2005-10-26 | 2010-06-29 | Bristol-Myers Squibb Company | Substituted thieno[3,2-D]pyrimidines as non-basic melanin concentrating hormone receptor-1 antagonists |
JP5193878B2 (ja) | 2005-12-21 | 2013-05-08 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | Mch−1が媒介する疾患における使用のための新規な置換ピラジノン誘導体 |
US7553836B2 (en) | 2006-02-06 | 2009-06-30 | Bristol-Myers Squibb Company | Melanin concentrating hormone receptor-1 antagonists |
TW200800920A (en) * | 2006-02-15 | 2008-01-01 | Sanofi Aventis | Novel azacyclyl-substituted arylthienopyrimidinones, process for their preparation and their use as medicaments |
EP1987042B1 (fr) | 2006-02-15 | 2015-01-21 | Sanofi | Nouvelles arylthiénopyrimidinones à substitution aminoalcool, leur procédé de préparation et leur utilisation comme médicaments |
EP1987006B1 (fr) | 2006-02-15 | 2011-01-12 | Sanofi-Aventis | Nouvelles aryldihydroisoquinolinones a substitution amino-alcool, procede pour les preparer et leur utilisation en tant que medicaments |
RU2008136898A (ru) | 2006-02-15 | 2010-03-20 | Санофи-Авентис (Fr) | Азациклил-замещенные арилдигидроизохинолиноны, способ их получения и их применение в качестве лекарственных средств |
EP2029609A2 (fr) * | 2006-06-08 | 2009-03-04 | Eli Lilly & Company | Nouveaux antagonistes de récepteur de mch |
EP2121703A4 (fr) | 2006-08-18 | 2011-12-28 | Astrazeneca Ab | Dérivés de thiénopyrimidin-4-one et de thiénopyridazin-7-one en tant qu'antagonistes du mch rl |
CN101679348A (zh) | 2007-01-10 | 2010-03-24 | 阿尔巴尼分子研究公司 | 5-吡啶酮取代的吲唑 |
EP2142554B1 (fr) | 2007-04-25 | 2015-01-14 | Bristol-Myers Squibb Company | Antagonistes du récepteur 1 de l'hormone de mélano-concentration non basiques |
WO2009015037A2 (fr) | 2007-07-21 | 2009-01-29 | Albany Molecular Research, Inc. | Indazoles substitués par du 5-pyridinone |
PE20091928A1 (es) | 2008-05-29 | 2009-12-31 | Bristol Myers Squibb Co | Tienopirimidinas hidroxisustituidas como antagonistas de receptor-1 de hormona concentradora de melanina no basicos |
EP2406233B1 (fr) * | 2009-03-09 | 2013-11-13 | Bristol-Myers Squibb Company | Analogues d'aza-pyridone utiles en tant que antagonistes des récepteurs de l'hormone concentrant la mélanine |
HUP1100241A3 (en) | 2011-05-06 | 2013-12-30 | Richter Gedeon Nyrt | Oxetane substituted pyrimidones |
KR20130013199A (ko) * | 2011-07-27 | 2013-02-06 | 한미약품 주식회사 | 신규 피리미딘 유도체 및 이를 활성성분으로 포함하는 약학 조성물 |
JP6283811B2 (ja) | 2011-08-26 | 2018-02-28 | オーエヌ ライト サイエンシーズ インコーポレイテッド | タトゥ除去システム及び方法 |
EP4076527A4 (fr) * | 2020-01-10 | 2024-05-15 | Consynance Therapeutics Inc | Polythérapies de médicaments et leurs méthodes d'utilisation |
HUP2200222A1 (hu) | 2022-06-17 | 2023-12-28 | Richter Gedeon Nyrt | MCHR1 antagonisták a Prader-Willi szindróma kezelésére |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0124627D0 (en) * | 2001-10-15 | 2001-12-05 | Smithkline Beecham Plc | Novel compounds |
-
2004
- 2004-10-21 KR KR1020067009417A patent/KR20060100412A/ko not_active Application Discontinuation
- 2004-10-21 WO PCT/US2004/034846 patent/WO2005042541A1/fr active Application Filing
- 2004-10-21 BR BRPI0415667-6A patent/BRPI0415667A/pt not_active IP Right Cessation
- 2004-10-21 US US10/576,765 patent/US20070078125A1/en not_active Abandoned
- 2004-10-21 EP EP04795941A patent/EP1678184A1/fr not_active Withdrawn
- 2004-10-21 CA CA002543122A patent/CA2543122A1/fr not_active Abandoned
- 2004-10-21 JP JP2006536779A patent/JP2007509158A/ja active Pending
- 2004-10-21 MX MXPA06003997A patent/MXPA06003997A/es unknown
- 2004-10-21 CN CNA2004800313000A patent/CN1871242A/zh active Pending
- 2004-10-21 AU AU2004285913A patent/AU2004285913A1/en not_active Abandoned
-
2006
- 2006-03-30 IL IL174693A patent/IL174693A0/en unknown
- 2006-04-20 ZA ZA200603181A patent/ZA200603181B/en unknown
- 2006-04-21 CO CO06038136A patent/CO5690599A2/es not_active Application Discontinuation
- 2006-04-25 MA MA28965A patent/MA28111A1/fr unknown
- 2006-04-28 NO NO20061909A patent/NO20061909L/no not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
MXPA06003997A (es) | 2006-07-05 |
KR20060100412A (ko) | 2006-09-20 |
CN1871242A (zh) | 2006-11-29 |
AU2004285913A1 (en) | 2005-05-12 |
CO5690599A2 (es) | 2006-10-31 |
NO20061909L (no) | 2006-05-03 |
US20070078125A1 (en) | 2007-04-05 |
ZA200603181B (en) | 2008-01-30 |
WO2005042541A1 (fr) | 2005-05-12 |
CA2543122A1 (fr) | 2005-05-12 |
BRPI0415667A (pt) | 2006-12-19 |
EP1678184A1 (fr) | 2006-07-12 |
JP2007509158A (ja) | 2007-04-12 |
IL174693A0 (en) | 2006-08-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA28111A1 (fr) | Derives des | |
MA30539B1 (fr) | Derives de piperazinyle utiles dans le traitement de maladies induites par le recepteur gpr38. | |
ATE422887T1 (de) | Kondensierte heterozyklische verbindungen | |
MA29693B1 (fr) | Derives de xanthine en tant qu'agonistes hm74a selectifs | |
ATE423769T1 (de) | Fluor- und sulfonylaminohaltige, 3,6- disubstituierte azabicyclo 3.1.0 hexanderivate als muscarinrezeptorantagonisten | |
SE9902987D0 (sv) | Novel compounds | |
HUP0100266A2 (hu) | NMDA-receptor-antagonista hatású 1-aminoalkilciklohexánszármazékok, a vegyületeket tartalmazó gyógyszerkészítmények és előállításaik | |
MA27448A1 (fr) | Derives de pyridine modulateurs du recepteur cb2 | |
ATE402935T1 (de) | Kondensierte heterocyclische verbindungen und deren verwendung als antagonisten des metabotropen rezeptors zur behandlung von gastrointestinalen erkrankungen | |
MA29839B1 (fr) | Derives de carboxamides servant d'antagonistes des recepteurs muscariniques | |
MA26722A1 (fr) | Nouveaux composes et medicaments les contenant | |
MA27144A1 (fr) | Benzamide et heteroarylamide servant d'antagonistes du recepteur p2x7 | |
MA30778B1 (fr) | Derives de sulfonamides servant d'agonistes adrenergique et d'antagonistes muscariniques | |
MA30999B1 (fr) | Composés. | |
MA30289B1 (fr) | Dérivés d'amines | |
TN2009000204A1 (fr) | Spirocetones servant d'inhibiteurs d'acetyl-coa-carboxylase | |
TNSN00092A1 (fr) | Composes nouveaux antagonistes de npy, procede pour leur preparation et compositions pharmaceutiques les contenant | |
MA27443A1 (fr) | Oxazoles et thiazoles nouveaux servant d'inhibiteurs du facteur de croissance transformant (tgf) | |
TW200510429A (en) | Heterocyclic MCHR1 antagonists | |
DE60237528D1 (de) | Neue aminoazetidin-, aminopyrrolidin- und aminopiperidinderivative | |
MA30696B1 (fr) | Derives de l'acide (3-amino-1,2,3,4-tetrahydro-9h-carbazol-9-yl)-acetique | |
EP2202222A3 (fr) | Dérivés d'indène, leur préparation et leur utilisation en tant que médicaments | |
EP2042490A3 (fr) | Dérivés du benzoimidazole comme antagonistes du recepteur Vanilloid | |
MA31941B1 (fr) | Bis-pyridylpyridones en tant qu'antagonistes du récepteur 1 de l'hormone de concentration de la mélanine | |
MA26541A1 (fr) | Nouvelles imidazolines, procede pour les preparer, compositions pharmaceutiques les contenant et leur utilisation dans le traitement de maladies soulagees par un traitement avec un antagoniste des recepteurs des prostaglandines |